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ABSTRACT 
 
The positive symptoms of schizophrenia primarily result from an excess of 
high affinity D2-like receptors (i.e. D2High receptors). First-generation 
antipsychotics, such as haloperidol, are D2-like antagonists that can cause 
severe extrapyramidal effects. Aripiprazole, a dopamine and serotonin partial 
agonist, has fewer side effects, making it tolerable for adults and children. 
Extrapyramidal effects (e.g. Parkinsonism, dystonia, and akathisia) are among 
the most problematic side effects produced by antipsychotic compounds, which 
likely result from an excess of D2-like receptors in the dorsal striatum. In order to 
examine the effects of repeated antipsychotic treatment on dopamine system 
functioning, this thesis compared the molecular effects of repeated haloperidol 
and aripiprazole administration on D2High receptors, as well as various indices of 
dopamine second messenger system functioning. Preadolescent and adult rats 
were pretreated with haloperidol or aripiprazole for 11 consecutive days. After 
either a 4- or 8-day drug abstinence period dorsal striatal tissue was extracted. 
[35S]GTPγS binding assays were conducted to assess the effects of repeated 
haloperidol and aripiprazole treatment on the efficacy and potency of D2-like 
receptors. PKA subunits and components of the Akt pathway were measured 
using Western Blots. Results showed that repeated treatment with haloperidol or 
aripiprazole did not significantly affect D2-like receptor efficacy or potency in 
young or adult rats. In both age groups, haloperidol significantly increased the 
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expression of PKA-Cα, PKA-Cβ, and PKA-RII, but not p-PKA. Haloperidol also 
significantly increased PKA-Cβ and PKA-RII levels relative to aripiprazole. 
Repeated administration of haloperidol significantly increased p-GSK-3β levels in 
young and adult rats, but neither haloperidol nor aripiprazole significantly affected 
GSK-3β, Akt, or p-Akt levels. Overall, the results of this thesis indicate that 
repeated aripiprazole and haloperidol treatment differentially affects D2 signaling 
pathways in the dorsal striatum. Aripiprazole has less extreme or prolonged 
effects on D2 receptor signaling pathways than haloperidol, as evidenced by the 
lack of post-treatment upregulation in the cAMP and Akt pathways. Upregulation 
of D2-like receptors and, in turn, upregulation of proteins in the cAMP and Akt 
pathways may be partially responsible for the side effects induced by long-term 
antipsychotic treatment.  
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CHAPTER ONE 
INTRODUCTION 
 
Approximately 4 out of 1,000 people around the world live with 
schizophrenia: a disorder that strains relationships and makes appropriate social 
interaction difficult (Stip & Tourjman, 2010). The DSM-V no longer classifies 
schizophrenia in categories (paranoid, disorganized, catatonic, undifferentiated, 
and residual), but rather it is based on a spectrum of symptoms (Bhati, 2013). 
According to the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; 
DSM-5; American Psychiatric Association, 2013) diagnosis consists of “two or 
more psychotic symptoms for six or more months” that can be acute, ongoing, or 
in either partial or full remission (Bhati, 2013). Diagnostic criteria for 
schizophrenia include the following symptoms: “delusions (e.g., beliefs not rooted 
in reality), hallucinations (e.g., sensory experiences not rooted in reality), 
disorganized speech (e.g., incoherent verbal communication), disorganized 
behavior or catatonia (e.g., inappropriate or unusual actions or movements), and 
negative symptoms (e.g., diminished motivation or behavior)” (American 
Psychiatric Association, 2013; Elis, Caponigro, & Kring, 2013, p. 915).  
Neural changes underlying these symptoms, as indicated by enlarged 
lateral ventricles and lower gray matter volumes in the frontal and medial 
temporal lobes, are generally consistent across adult patients (Fusar-Poli et al., 
2013; Shenton, Dickey, Frumin, & McCarley, 2001; Shepard, Laurens, Matheson, 
2 
 
Carr, & Green, 2012). MRI studies show that neural changes progress as the 
brain matures; however, the brains of adults with advanced symptoms of 
schizophrenia have similar amounts of damage, suggesting that at some point 
during maturation this progression stabilizes (Andreasen et al., 2011; Olabi et al., 
2011; Pantelis et al., 2005). Recent clinical studies have focused on the 
prodromal symptoms of schizophrenia in children and adolescents in an attempt 
to understand the development of the disorder (Woodberry et al., 2014). 
Evidence suggests that there is a strong genetic predisposition for schizophrenia, 
and these individuals may be vulnerable to the development of the disorder at 
various points during maturation: prenatal, perinatal, childhood, and post-
adolescence (Cannon, 2005; Pantelis et al., 2005; Walder, Faraone, Glatt, 
Tsuang, & Seidman, 2014). Environmental factors, such as prenatal exposure to 
infection, malnutrition, toxins, obstetric complications, stress due to social 
isolation or familial conflict, brain injury, and drug use, contribute to the onset of 
schizophrenia at these vulnerable periods (Brown, 2011; McDonald & Murray, 
2000; Seeman & Seeman, 2014). 
Although probably involving a complex interplay between various 
neurotransmitter systems, the positive symptoms of schizophrenia primarily 
result from dopamine system dysfunction. Three brain areas likely to be involved 
are the prefrontal cortex, nucleus accumbens, and dorsal striatum (Krug et al., 
2014; Rausch et al., 2014). Clinical efforts focus on reducing dopamine 
transmission through the use of dopamine receptor antagonists or partial 
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agonists. Specifically, the D2-like receptors, which include the D2, D3, and D4   
subtypes, are linked to schizophrenia (Glatt, Faraone, & Tsuang, 2003; Shafer & 
LeVant, 1998; Wang, Zhong, Gu, & Yan, 2003). D2-like receptors can function in 
two different states: a state of high affinity and a state of low affinity (i.e. D2High 
and D2Low receptors; Seeman, 2011). Indeed, Seeman (2011) has proposed that 
an excess of D2High receptors is responsible for the positive symptoms associated 
with schizophrenia.  
First-generation antipsychotics or “typical antipsychotics” emerged as a 
treatment for schizophrenia in the 1950’s, followed by second-generation anti-
psychotics or “atypical antipsychotics” in the 1980’s (Abou-Setta et al., 2012). 
First-generation antipsychotics are potent dopamine D2-like receptor 
antagonists, which exhibit a dose-dependent correlation between clinical 
effectiveness and affinity for D2-like receptors (Mailman & Murthy, 2010). Despite 
their clinical efficacy, first-generation antipsychotics have many undesirable side 
effects, including sedation, autonomic and cardiovascular changes, weight gain, 
extrapyramidal side effects (i.e. Parkinsonism, dystonia, and akathisia), 
neuroendocrine effects, and tardive dyskinesia (Mailman & Murthy, 2010). 
Extrapyramidal side effects can become permanent, and the acetylcholinergic 
drugs used to treat these motor deficits have their own set of side effects (dry 
mouth, constipation, delirium, and memory problems) (Mailman & Murthy, 2010). 
As a consequence, many patients are reluctant to take first-generation 
antipsychotics, as evidenced by the number of patients who stop long-term 
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treatment (Warikoo, Chakrabarti, & Grover, 2014); thus making the search for an 
effective antipsychotic with few complications both necessary and complex.  
Second-generation antipsychotics (such as amisulpride, clozapine, 
olanzapine, and risperidone) cause a reduction of positive symptoms, and 
produce fewer side effects than first-generation antipsychotics (Croxtall, 2012; 
Leucht et al., 2009). Even so, second-generation antipsychotics do have some 
side effects, such as weight gain, myocarditis, sexual dysfunction, and acute 
extrapyramidal symptoms (Gardner, Baldessarini, & Waraich, 2005; Shirzadi & 
Ghaemi, 2006; Uçok & Gaebel, 2008). Patients may be just as likely to 
discontinue taking second-generation antipsychotics as first-generation 
antipsychotics, since long-term preference for either first- or second-generation 
drugs remains inconclusive (Warikoo et al., 2014). Overall, first- and second-
generation antipsychotics appear about equally effective at mitigating positive 
symptoms, but neither are particularly effective at reducing negative symptoms 
(Leucht et al., 2009; McEvoy, Zygman, & Margolese, 2010; White et al., 2006).  
Today, 20 first-generation and second-generation antipsychotics are approved by 
the Food and Drug Administration for the treatment of schizophrenia, and some 
drugs are used off-label for the treatment of other disorders (Abou-Setta et al., 
2012).  
 Despite these advances, there is a continuing desire to develop drugs with 
a superior side effect profile and a greater efficacy for treating negative 
symptoms. Aripiprazole is a dopamine and serotonin partial agonist with a high 
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affinity for D2-like receptors, thus placing it in a class of its own as a “third-
generation” antipsychotic. Aripiprazole is recognized throughout the literature for 
its efficacy, tolerability among patients, and its ability to reduce symptoms of 
other mental disorders, including off-label use for severe agitation in geriatric 
dementia patients (Leslie, Mohamed, & Rosenheck, 2009; Maglione et al., 2009; 
Shekelle et al., 2007). Additionally, aripiprazole may be more effective than other 
drugs at treating negative symptoms (DeLeon, Patel, & Crismon, 2004; Naber & 
Lambert, 2004; Stip & Tourjman, 2010), although some studies suggest that 
aripiprazole and second-generation antipsychotics do not differ according to 
negative symptom reduction (Bianchini et al., 2014). According to Kirino (2012) 
aripiprazole has fewer side effects than other antipsychotics, although some 
aversive symptoms have been reported. Interestingly, actions at serotonin 
receptors may be involved in the muted extrapyramidal effects experienced after 
repeated aripiprazole treatment, since serotonin receptor antagonism increases 
dopaminergic transmission and, thus, could soften dopamine receptor 
upregulation in the dorsal striatum (Kapur & Mamo, 2003; Kuroki, Nagao, & 
Nakahara, 2008; Meltzer, Li, Kaneda, & Ichikawa, 2003). Aripiprazole was 
approved by the Food and Drug Administration in 2002 for the treatment of 
schizophrenia (Kirino, 2012). 
 Due to the high tolerability of aripiprazole, it is also administered to 
children and adolescents diagnosed with schizophrenia (ages 13-17) and bipolar 
disorder I (ages 10-17), either alone or in conjunction with lithium or valproate 
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(Kirino, 2012). Aripiprazole has also been administered to children for tic 
disorders, autism, aggression or conduct disorder, and depression (Masi et al., 
2009; Stachnik & Nunn-Thompson, 2007; Yoo et al., 2011). The few studies 
assessing the long-term effects of aripiprazole in children are promising. Yoo et 
al. (2011) compared the effects of the first-generation antipsychotic haloperidol to 
aripiprazole, and found that the two drugs were equally efficacious at reducing tic 
symptoms, but aripiprazole had fewer side effects.  
 In summary, haloperidol and aripiprazole are equally effective at reducing 
positive symptoms in patients with schizophrenia, with aripiprazole being more 
efficacious when treating negative symptoms. Haloperidol is associated with 
pronounced side effects, most notably hyperprolactinemia and extrapyramidal 
symptoms; whereas, the development of hyperprolactinemia, weight gain, and 
sedation is generally much lower with aripiprazole (Kane et al., 2002; Marder et 
al., 2003; McEvoy, Daniel, Carson, McQuade, & Marcus, 2007). With this 
information as a backdrop, the purpose of this thesis is to compare the effects of 
haloperidol and aripiprazole at a molecular level across ontogeny, in order to 
determine the basis for these different treatment outcomes in humans. To this 
end, I assessed the effects of haloperidol and aripiprazole on D2High receptors 
and various indices of second messenger system functioning (e.g. protein kinase 
A subunits and Akt levels). Understanding the neuronal effects of these 
compounds in preadolescent and adult rats could help explain the unique 
treatment and side effect profiles of first-, second-, and third-generation 
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antipsychotics and expose potential ontogenetic differences in receptor 
functioning.  
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CHAPTER TWO 
DOPAMINE SYSTEMS IN ADULT RODENTS 
 
Overview of Dopamine Pathways and Schizophrenia   
 The mammalian brain contains four prominent dopamine pathways: 
nigrostriatal, mesolimbic, mesocortical, and tuberoinfundibular. Dysregulation of 
dopamine systems within two of these pathways is thought to underlie the 
symptoms of schizophrenia (Davis, Kahn, Ko, & Davidson, 1991). The positive 
symptoms of schizophrenia are attributed to hyperdopaminergia in the 
mesolimbic pathway, while negative symptoms are attributed to 
hypodopaminergia in the mesocortical pathway (Davis et al., 1991). Additionally, 
dopamine antagonism in the nigrostriatal dopamine pathway is responsible for 
extrapyramidal side effects (Nguyen, Pradel, Micallef, Montastruc, & Blin, 2004; 
Ossowska, 2002). 
 Dahlström and Fuxe (1964) categorized dopaminergic cells into nine 
clusters within the rat brain, with higher concentrations of dopamine in the rostral 
mesencephalon and lower concentrations of dopamine in the diencephalon. This 
patterning suggests that dopamine fibers project from caudal to rostral areas 
(Dahlström & Fuxe, 1964). Further research showed that clusters of cells 
containing high levels of dopamine originate in the ventral tegmental area and 
the substantia nigra pars compacta (Beckstead, Domesick, & Nauta, 1979; 
Moore & Bloom, 1978; Smith & Kieval, 2000). The axons of cells located in the 
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ventral tegmental area extend to the ventral striatum (nucleus accumbens), and 
are referred to as the mesolimbic pathway (Björklund & Dunnett, 2007). Some 
neurons project directly from the ventral tegmental area to the prefrontal cortex, 
and this pathway is known as the mesocortical pathway (Emson & Koob, 1978; 
Fuxe et al., 1974). The two pathways projecting to the nucleus accumbens are 
sometimes jointly referred to as the mesocorticolimbic pathway (White, 1996). 
The axons of cells located in the substantia nigra terminate in the dorsal striatum 
(caudate nucleus and putamen), which is known as the nigrostriatal pathway 
(Hanley & Bolam, 1997; Matsuda et al., 2009; Prensa & Parent, 2001). A fourth 
pathway, labeled the tuberoinfundibular pathway, projects from the hypothalamus 
to the anterior pituitary (Ben-Jonathan, Arbogast, & Hyde, 1989; Gudelsky, 1981; 
McCann et al., 1986).  
 
Mesolimbic Pathway 
Ventral Tegmental Area 
Dorsal to the substantia nigra, the ventral tegmental area is involved in 
reward, motivation, and cognition (Lewis & O’Donnell, 2000). The ventral 
tegmental area is divided into four sections: the paranigral nucleus, the 
parabrachial pigmented area, the parafasciculus retroflexus area, and the ventral 
tegmental tail (Oades & Halliday, 1987). Both the paranigral and parabrachial 
pigmented areas contain high concentrations of dopaminergic cells, whereas the 
parafasciculus retroflexus area and the ventral tegmental tail contain much lower 
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concentrations (Ikemoto, 2007). The ventral tegmental tail contains GABAergic 
neurons that inhibit the firing of dopaminergic neurons within other portions of the 
ventral tegmental area. The prominent tract projecting from the ventral tegmental 
area innervates the nucleus accumbens, olfactory tubercle, amygdala, septal 
area, and the anterior limbic area (Ikemoto, 2007; Swanson, 1982).  
Nucleus Accumbens 
The nucleus accumbens, also known as the ventral striatum, is composed 
of a core and a shell (Heimer, Zahm, Churchill, Kalivas, & Wohltmann, 1991). 
Dopaminergic cells are robustly located in the shell, with few dopaminergic 
neurons found in the core (Deuscht & Cameron, 1992; Zahm, 1992). 
Dopaminergic afferents innervate the shell from the ventral tegmental tail in 
addition to limbic structures such as the hippocampus, lateral hypothalamus, 
entorhinal cortex, and amygdala (Deuscht & Cameron, 1992). Neurons located in 
the shell exhibit two main structural distinctions from neurons in the core. 
Namely, neurons in the shell have fewer dendritic spines and fewer terminals 
than do neurons located in the core (Meredith, Agolia, Arts, Groenewegen, & 
Zahm, 1992). Evidence suggests that dopaminergic release in the nucleus 
accumbens is modulated by glutamatergic afferents from the prefrontal cortex 
and the basal lateral amygdala (Jackson & Moghaddam, 2001).  
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Mesocortical Pathway  
Neurons that comprise the mesocortical pathway project from the ventral 
tegmental area to limbic and medial prefrontal cortices (Björklund & Dunnett, 
2007; Voorn, Jorritsma-Byham, Van Dijk, & Buijs, 1986). Most notably, neurons 
in the paranigral and parabrachial nuclei of the ventral tegmental area project to 
the medial prefrontal cortex (Lammel et al., 2008; Oades & Halliday, 1987; 
Ranganath & Jacob, 2015). The medial prefrontal cortex is located in the most 
rostral area of the brain near the midline. In rats, it is functionally involved in 
working memory, attention, and inhibitory response control, although cognitive 
abilities associated with the prefrontal cortex vary among species (Dalley, 
Cardinal, & Robbins, 2004; Heidbreder & Groenwegen, 2003; Ranganath & 
Jacob, 2015). In addition to these more prominent limbic and cortical projections, 
neurons originating in the ventral tegmental area also terminate in the thalamus, 
periaqueductal gray, parabrachial nucleus, locus coeruleus, and the median 
raphe nucleus (Swanson, 1982). 
 
Nigrostriatal Pathway 
Substantia Nigra 
The substantia nigra contains a large concentration of dopaminergic 
neurons. It is subdivided into two nuclei: the substantia nigra pars compacta and 
the nondopaminergic substantia nigra pars reticulata. The pars compacta and 
pars reticulata are associated with the control of voluntary movement. 
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Dopaminergic neurons located in the substantia nigra pars compacta project to 
the dorsal striatum (caudate nucleus and putamen), globus pallidus, and 
entopeduncular nucleus (Gauthier, Parent, Lévesque, & Parent, 1999; Gerfen, 
Staines, Fibiger, & Arbuthnott, 1982). A higher concentration of these neuronal 
cell bodies reside in the rostral portion of the substantia nigra pars compacta in 
comparison to the caudal region (Tieu, 2011).   
Dorsal Striatum  
The caudate nucleus, which is a component of the dorsal striatum, is 
essential for the control of voluntary movement. The caudate nucleus lies 
adjacent to the thalamus and the anterior horn of the lateral ventricle. 
Dopaminergic efferents from the substantia nigra terminate in the caudate 
nucleus (Gauthier, Parent, Lévesque, & Parent, 1999; Matsuda et al., 2009; 
Nelson & Kreitzer, 2014), with outputs extending to the subthalamic nucleus and 
globus pallidus. The putamen, a second component of the dorsal striatum, also 
plays a critical role in the regulation of voluntary movement, and it is structurally 
and functionally associated with the caudate nucleus in rodents.  
Subthalamic Nucleus 
The subthalamic nucleus consists mainly of glutamatergic neurons that 
have a modulatory effect on dopamine pathways. Located posteromedially to the 
substantia nigra, the subthalamic nucleus modulates voluntary movement, as 
lesions to the subthalamic nucleus result in contralateral hemiballismus (Hamani, 
Saint-Cyr, Fraser, Kaplitt, & Lozano, 2004). The subthalamic nucleus receives 
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dopaminergic input from the dorsal striatum, and maintains a feedback loop with 
the globus pallidus.  
Globus Pallidus 
The globus pallidus is an integrated structure in rats, whereas in primates 
the globus pallidus has distinct external and internal components. The globus 
pallidus is located caudally to the dorsal striatum and is involved in controlling 
voluntary movement. The globus pallidus receives afferents from the substantia 
nigra, caudate nucleus, putamen, and subthalamic nucleus (Kita & Kita, 2001). 
GABAergic neurons in the globus pallidus project to the lateral and anterior 
nuclei of the thalamus and the subthalamic nucleus (Bevan, Booth, Eaton, & 
Bolam, 1998).  
Entopeduncular Nucleus 
The entopeduncular nucleus can be found in non-primate mammals and is 
located lateral to the hypothalamus. This area corresponds to the medial 
pallidum in primates (Benhamou & Cohen, 2014), and is functionally similar to 
the globus pallidus. The entopeduncular nucleus receives dopaminergic afferents 
from the substantia nigra pars compacta and projects GABAeric fibers to the 
thalamus.  
Thalamus  
 The thalamus is comprised of nuclei that synthesize information about 
sensory stimuli and voluntary movement. Among the many nuclei, the 
ventromedial nucleus of the thalamus is involved in motor control in rats (Clavier, 
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Atmadja, & Fibiger, 1976).  Efferents from the putamen and entopeduncular 
nucleus converge in the ventromedial thalamus, while outputs from the thalamus 
project to the supplementary motor area, the cerebellum, and the spinal cord.  
 
Tuberoinfundibular Pathway  
Hypothalamus 
The hypothalamus is located below the thalamus and is a highly 
interconnected region comprised of many small nuclei involved in the regulation 
of the endocrine system and other homeostatic mechanisms (DeGroot, 1959; 
Reichlin, Saperstein, Jackson, Boyd, & Patel, 1976). As a consequence, the 
hypothalamus regulates the sympathetic nervous system and modulates stress, 
sleep, body temperature, physical growth, metabolism, sexual maturation, 
ovulation and spermatogenesis, lactation, hunger, and thirst (Besser & Mortimer, 
1974; Schally, Kastin, & Arimura, 1977). The tuberoinfundibular pathway, which 
projects from the arcuate and paraventricular nuclei of the hypothalamus to the 
anterior pituitary, releases dopamine at the target site.    
Anterior Pituitary 
The pituitary gland contains an anterior lobe (adenohypophysis) and a 
posterior lobe (neurohypophysis). The neurosecretory cells in the anterior lobe 
release various hormones into the blood (e.g. growth hormone, luteinizing 
hormone, follicle-stimulating hormone, thyroid-stimulating hormone, ACTH, and 
prolactin) (Ben-Jonathan, Arbogast, & Hyde, 1989; Besser & Mortimer, 1974; 
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Buckingham, 1981; Schally et al., 1977). Dopaminergic efferents from the 
tuberoinfundibular pathway inhibit the release of prolactin (Enjalbert et al., 1986; 
Macleod & Lehmeyer, 1974; Maurer, 1980). Prolactin is primarily known for 
inducing lactation in mammals, but also regulates water and electrolyte balance, 
growth, metabolism, parental behavior, reproduction, and immunoregulation 
(Bole-Feysot et al., 1998). 
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CHAPTER THREE 
DOPAMINE RECEPTORS IN ADULT RODENTS 
 
Dopamine Receptor Subtypes and the cAMP Signaling Pathway 
Dopamine receptors are relatively homologous, but they are classified 
functionally based on their modulation of adenylyl cyclase via G protein coupled 
receptors (Beaulieu & Gainetdinov, 2011; Missale, Nash, Robinson, Jaber, & 
Caron, 1998). D1-like receptors include both D1 receptors (D1A receptors in rats) 
and D5 receptors (D1B receptors in rats) (Emilien, Maloteaux, Geurts, 
Hoogenberg, & Cragg, 1999). When an agonist binds to D1 or D5 receptors, Gsα 
and Golfα subunits detach from the β and γ subunits through the exchange of 
guanosine diphosphate (GDP) for guanosine triphosphate (GTP). This triggers 
an increase in adenylyl cyclase activity, which causes adenosine triphosphate 
(ATP) to lose two phosphate groups and become adenosine monophosphate, or 
cyclic AMP (cAMP). Cyclic AMP stimulates protein kinase A (PKA), which 
consequently regulates protein transcription and gene expression.  
Receptors in the D2-like subclass, which include D2, D3, and D4 receptors, 
activate the G protein subunit Giα. As the Giα subunit dissociates from the βγ 
complex, through the exchange of GDP for GTP, adenylyl cyclase is inhibited. 
Inhibition of adenylyl cyclase results in decreased cAMP levels and PKA activity 
which, in turn, suppresses protein transcription and gene expression (Beaulieu & 
Gainetdinov, 2011; Missale et al., 1998). Thus, PKA is active when cAMP binds 
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to the PKA regulatory subunit, causing the alpha and beta catalytic subunits to 
separate (Dell’Acqua & Scott, 1997; Hubbard & Cohen, 1993).  
 
D2 Receptors and the Akt Signaling Pathway 
Akt, also referred to as Protein Kinase B, is a serine/threonine kinase that 
is part of a D2 receptor second messenger cascade involved in the gene 
regulation of cell proliferation and apoptosis (Brunet, Datta, & Greenberg, 2001; 
Kennedy et al., 1997; Song, Ouyang, & Bao, 2005). Thus, this pathway plays an 
important role in normal functioning of dopamine-regulated behaviors and is 
distinct from the cAMP pathway (Arguello & Gogos, 2008; Li & Gao, 2011). 
Activation of the Akt signaling pathway appears to be unique to D2 receptors, but 
may be augmented by D3 receptors (Beaulieu et al., 2007). When dopamine 
binds to D2 receptors, the phosphorylation of Giα by G protein receptor kinases 
signals β-arrestin2 to activate protein phosphatase 2A (PP2A). PP2A inhibits Akt, 
which inhibits glycogen synthase kinase 3 (GSK-3β) (Beaulieu, Del’Guidice, 
Sotnikova, Lemasson, & Gainetdinov, 2011; Li & Gao, 2011). GSK-3β, in turn, 
inhibits β-catenin. Evidence suggests that the Akt signaling pathway is active 
under hyperdopaminergic conditions, and β-catenin may mediate synaptic 
plasticity via glutamatergic AMPA and NMDA receptors (Li & Gao, 2011). When 
D2 receptors are stimulated by an agonist, the inhibitory effects of GSK-3β on β-
catenin are disinhibited due to the inhibition of Akt by PP2A, thus attenuating the 
modulatory effects of β-catenin (Beaulieu et al., 2011).  
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D1-like Receptor Localization 
In terms of the D1-like receptor family, D1 receptors are the most prolific 
dopamine receptor subtype and are found densely in the striatum, nucleus 
accumbens, substantia nigra pars reticulata, olfactory bulb, amygdala, frontal 
cortex, hippocampus, cerebellum, thalamus, and hypothalamus (Beaulieu & 
Gainetdinov, 2011; Dawson, Ghelert, Yamamura, Barnett, & Wamsley, 1985). 
High concentrations of D1 receptors are found in the entopenduncular nucleus 
and the islands of Calleja, with moderate to low concentrations in the frontal 
cortex and subthalamic nucleus (Dawson et al., 1985; Emilien et al., 1999). 
Additionally, high levels of D1 receptor mRNA are located in the striatum, nucleus 
accumbens, olfactory tubercle, amygdala, and anterior cingulate cortex (Meador-
Woodruff, 1991, 1994). Low levels of D1 mRNA are found in the septum, 
hippocampus, hypothalamus, thalamus, cerebellum, and cortex (Meador-
Woodruff, 1991, 1994).  
D5 receptors are less abundant than other dopamine receptor subtypes 
and are found primarily on pyramidal neurons of the prefrontal cortex, premotor 
cortex, cingulate cortex, entorhinal cortex, olfactory tubercle, substantia nigra 
pars compacta, hypothalamus, hippocampus, and dentate gyrus (Beaulieu & 
Gainetdinov, 2011). Relatively low levels of D5 receptors are also located on the 
medium spiny neurons of the caudate nucleus and the nucleus accumbens 
(Beaulieu & Gainetdinov, 2011; Khan et al., 2000). Moderate levels of D5 
receptor mRNA are detected in the parafascicular nucleus of the thalamus and 
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hippocampus (Meador-Woodruff, 1992, 1994). Additionally, high levels of D5 
receptor mRNA are found in the endoperiform, reuniens and perifascicular nuclei 
of the thalamus (Apostolakis et al., 1996).  
 
D2-like Receptor Localization 
D2 receptors are the most abundant of the D2-like receptors and are found 
in many of the same locations as D1 receptors (Boyson, McGonigle, & Molinoff, 
1986). Higher concentrations of D2 receptors are evident in the striatum, nucleus 
accumbens, olfactory tubercle, substantia nigra, ventral tegmental area, 
hypothalamus, striate cortex, entorhinal cortex, choroid plexus, islands of Calleja, 
septum, amygdala, hippocampus, pituitary gland, and retina (Boyson et al., 1986; 
Charuchinda, Supavilai, Karobath, & Palacios, 1987; Gehlert & Wamsley, 1986). 
D2 receptor mRNA is abundant in the substantia nigra, ventral tegmental area, 
and zona incerta (Meador-Woodruff, 1991, 1994). Additionally, high levels of D2 
mRNA are located in the striatum, nucleus accumbens, olfactory tubercle, and 
entorhinal cortex, with moderate levels in the anterior cingulate, orbital and 
insular cortices. In contrast, low levels of D2 receptor mRNA are found in the 
septum, amygdala, hippocampus, cortex, hypothalamus, thalamus, and 
cerebellum (Meador-Woodruff, 1991, 1994). D2 receptors have two distinct 
isoforms: D2 short (D2S) and D2 long (D2L). D2S receptors are located 
presynaptically and function as dopamine autoreceptors, whereas D2L receptors 
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are located postsynaptically (Jomphe, Tiberi, & Trudeau, 2005; Lindgren et al., 
2003; Usiello et al., 2000).  
 The highest densities of D3 receptors are predominately found in the shell 
of the nucleus accumbens, olfactory tubercle, islands of Calleja, ventral pallidum, 
substantia nigra, and cerebellum (Lévesque et al.,1992; Stanwood et al., 2000). 
Lower numbers of D3 receptors are found in the striatum, ventral tegmental area, 
hippocampus, septum, and prefrontal cortex (Beaulieu & Gainetdinov, 2011; 
Lévesque et al.,1992). Not surprisingly, D3 receptor mRNA is highly expressed in 
the nucleus accumbens and islands of Calleja, with low levels in the substantia 
nigra, ventral tegmental area, striatum, septum, olfactory tubercle, amygdala, 
hippocampus, cortex, hypothalamus, thalamus, and cerebellum (Lévesque et 
al.,1992; Meador-Woodruff, 1991, 1994).  
D4 receptors are the least common of the D2-like receptors and are 
expressed in relatively low levels in the hippocampus, striatum, olfactory 
tubercle, amygdala, hypothalamus, globus pallidus, substantia nigra, nucleus 
accumbens core, thalamus, frontal and entorhinal cortices, and cerebellum 
(Defagot & Antonelli, 1996; Defagot, Malchiodi, Villar, & Antonelli, 1997; Primus 
et al., 1997; Tarazi, Kula, & Baldessarini, 1997). D4 receptor mRNA is located in 
the substantia nigra and ventral tegmental area (Meador-Woodruff, 1994), while 
low levels of D4 receptor mRNA are expressed in the nucleus accumbens, 
amygdala, hippocampus, cortex, hypothalamus, and thalamus (Meador-
Woodruff, 1994).  
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D2High Receptor Affinity and Functionality  
 As mentioned in Chapter 1, D2-like receptor systems are intimately 
associated with psychosis. D2-like receptors exist in two different functional 
states: a state of high affinity and a state of low affinity (Seeman, 2011). The 
high-affinity state of the D2-like receptor, known as D2High, is thought to be 
responsible for dopamine supersensitivity, which is most commonly observed as 
an exaggerated behavioral response to agonist drugs. Various manipulations 
increase D2High receptors and produce dopamine supersensitivity, including 
ethanol treatment and withdrawal, hippocampal lesion, amphetamine- or 
quinpirole-induced sensitization, Cesarean section, cocaine self-administration, 
and excitotoxic lesions of the entorhinal cortex (Briand, Flagel, Seeman, 
Robinson, 2008; Seeman et al., 2005; Sumiyoshi et al., 2005). Among humans, 
dopamine agonists can trigger psychotic symptoms in normal populations and 
exacerbate psychosis in schizophrenics (Angrist, Rotrosen, & Gershon, 1980; 
Bell, 1973; Ellison, 1994). Thus, the positive symptoms characteristic of 
schizophrenia may not result from a simple increase in D2-like receptor numbers 
in particular dopaminergic pathways, but rather a change in the functionality of 
the D2-like receptors. Specifically, Seeman (2011) has proposed that an 
increased proportion of D2High receptors relative to D2Low receptors is responsible 
for schizophrenia. Therefore, an increased percentage of D2High receptors may 
underlie the hyperdopaminergia of the mesolimbic dopamine pathway (Davis et 
al., 1991).  
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CHAPTER FOUR 
DOPAMINE SYSTEMS AND RECEPTORS IN YOUNG RODENTS  
 
Overview 
 Dopamine neurons increase steadily in number from the prenatal period 
through adolescence (Tarazi & Baldessarini, 2000). Around PD40, dopamine 
receptor levels peak and a period of pruning occurs in which receptors decline to 
adult levels at PD60 through PD120 (Andersen, Thompson, Rutstein, Hostetter, 
& Teicher, 2000; Teicher, Andersen, & Hostetter, 1995). Dopamine neurons are 
apparent at embryonic day (E)13 in the prosencephalon; and by E14 two 
prominent clusters of dopamine neurons extend from the mesencephalon to the 
ganglionic eminence (Voorn, Kalsbeek, Jorritsma-Byham, & Groenewegen, 
1988). By E17, these trajectories innervate the dorsal striatum, and dopamine 
neurons further differentiate into distinct clusters that form the substantia nigra, 
VTA, dorsal striatum, nucleus accumbens, and olfactory tubercles (Fishell & van 
der Kooy, 1987; Voorn et al., 1988). Rostral dopaminergic afferents also spread 
to the area of the future prefrontal cortex (Kalsbeek, Voorn, Buijs, Pool, & 
Uylings, 1988). Dopamine neurotransmitter levels during early development (E18 
to PD5) are about 8-17% of adult levels (Noisin & Thomas, 1988).  
 By the first postnatal day (PD1), dopamine neurons in the substantia nigra 
exist in small distinct clusters. These clusters more closely resemble adult 
distributions by PD4 and continue to increase in size through PD11 (Fishell & van 
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der Kooy, 1987; Murrin & Ferrer, 1984). Around PD4, dopamine neurons 
innervate the nascent prefrontal cortex (Kalsbeek et al., 1988). Dopamine 
neurons throughout the dorsal striatum continue to develop from PD8 through 
PD13 (Voorn et al., 1988). A shift in development occurs in the dorsal striatum 
during adolescence, as dopamine receptor levels peak at PD40 and then decline 
to adult levels by PD60 (Teicher et al., 1995). This developmental pattern is 
apparent in the dorsal striatum, but similar changes in receptor density are also 
observed in the nucleus accumbens (Teicher et al., 1995). Overall, dopamine 
neurotransmitter levels fluctuate during development and are heterogeneous 
across brain areas. Dopamine levels eventually stabilize at adult levels at 
different time points depending on brain region, but adult dopaminergic systems 
are established by PD120 (Andersen et al., 2000; Rao, Molinoff, & Joyce, 1991).   
 
Overview of Dopamine Receptor Subtype Development  
 In the dorsal striatum, D1-like and D2-like receptors increase at similar 
rates, thus suggesting that development of the two receptor subtypes are 
controlled by similar mechanisms (Zeng, Hyttel, & Murrin, 1988). Despite a 
general increase in receptors with age, the emergence of D1-like and D2-like 
receptors is non-linear, since the dorsal striatum, substantia nigra, and globus 
pallidus contain heterogeneous levels of receptor subtypes at any given age 
(Rao et al., 1991).  Within the dorsal striatum and nucleus accumbens, D1, D2, 
and D4 receptors reach peak levels at PD28 and decline to adult levels between 
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PD35 and PD60 (Tarazi & Baldessarini, 2000). Limbic and cortical structures 
also demonstrate a similar developmental pattern, with a relative absence of 
pruning during adolescence (Tarazi & Baldessarini, 2000). D1 and D2 receptor 
mRNA is apparent before dopaminergic innervation, however postnatal 
dopamine receptor binding correlates with dopamine innervation (Jung & 
Bennett, 1996). At birth, D1-like and D2-like receptor mRNA is at about 60% of 
adult levels, with mRNA levels peaking at PD30, and then declining to adult 
levels (Creese, Sibley, & Xu, 1992).  
 
D1-like Receptor Localization 
 Embryonic development of D1-like receptors increases slowly from E14 
through birth (Jung & Bennett, 1996). Early evidence suggested that the number 
of D1-like receptors stabilizes between birth and seven postnatal weeks 
(Broaddus & Bennett, 1989); however, it is more generally reported that D1-like 
receptors double in number every 7 to 10 days for the first 3 weeks (Murrin & 
Zeng, 1990; Zeng et al., 1988). This pattern of development is clearly evident in 
areas such as the dorsal striatum, nucleus accumbens, and olfactory tubercle, 
but the same pattern is also apparent in brain regions with more moderate levels 
of D1-like receptors such as the frontal cortex, claustrum, and endoperiform 
nucleus (Murrin & Zeng, 1990). The function of the D1-like receptor is unaltered 
during maturation, since juvenile D1-like receptors exhibit the same 
pharmacological properties as adult D1-like receptors (Zeng et al., 1988). For 
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example, D1-like receptors are coupled to their G-proteins by PD5 (Jung & 
Bennett, 1996). D1-like receptor levels increase steadily throughout the 
developing brain until adolescence. At PD40, D1-like receptor densities in the 
dorsal striatum peak and then decline to adult levels where they remain relatively 
stable from PD60 through PD140 (Teicher et al., 1995). D1-like receptor mRNA 
is apparent by E14 in the dorsal striatum, olfactory tubercle, frontal, cingulate, 
parietal, and insular cortices, epithalamus, thalamus, hypothalamus, and pons. 
By E18, mRNA localization parallels that of adults (Schambra et al., 1994). In the 
nigrostriatal pathway, D1-like receptor mRNA increases linearly until birth, peaks 
at PD5, and then decreases by 20% until adult levels are maintained (Jung & 
Bennett, 1996).  
 
D2-like Receptor Localization 
 D2 receptors are the most abundant and diffuse of the D2 receptor family 
(Stanwood, McElligot, Lu, & McGonigle, 1997). Even so, most studies examining 
the ontogeny of D2-like receptors use displacing ligands that do not differentiate 
among the D2-like receptor subtypes. Despite this issue, D2-like receptor 
autoradiography is a good estimate of D2 receptor distribution due to the 
relatively large number of D2 receptors compared to D3 and D4 receptors 
(Stanwood et al., 1997). At E12, D2-like receptors are found in the caudal part of 
the neural tube and extend outward to regions that will comprise the forebrain. 
This pattern of development leads to a dramatic increase in the number of dorsal 
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striatal receptors between E15 through E17 (Sales, Martres, Bouthenet, & 
Schwartz, 1989). Large increases in D2-like receptor levels occur from E18 
through E22 across the forebrain, and this late prenatal period is also 
characterized by the emergence of D2-like receptors in the olfactory tubercles 
(Sales et al., 1989). Generally, D2-like receptors increase linearly in number from 
PD2, and approach adult levels by PD21 (Murrin & Zeng, 1986; Stanwood et al., 
1997). D2-like receptor numbers and G-protein-induced inhibition of adenylyl 
cyclase increases between PD21 through PD28, which coincides with a 
substantial increase in dopamine terminals in the dorsal striatum (Broaddus & 
Bennett, 1989). In terms of D2-like receptor subtypes, expression of D2 receptors 
antecedes expression of D3 receptors, since D3 receptors emerge at a slower 
rate in the dorsal striatum and nucleus accumbens than D2 receptors (Stanwood 
et al., 1997). D3 receptors are detectable by PD14 in the islands of Calleja and by 
PD21 in the nucleus accumbens. D3 receptors show a steady increase in 
numbers until PD60 (Stanwood et al., 1997). In terms of receptor affinity, the D2-
like receptors of young and adult rats show a similar binding affinity (i.e. Kd) by 
PD7 (Murrin & Zeng, 1986). 
 D2-like receptor mRNA is present at E14 in the dorsal striatum, olfactory 
tubercle, frontal, cingulate, parietal, and insular cortices, epithalamus, thalamus, 
hypothalamus, and pons (Schambra et al., 1994; Srivastava, Morency, & Mishra, 
1992). At E18, D2-like receptor mRNA dispersion is similar to what is observed in 
adult rat brains, although D2-like receptor mRNA levels show a different pattern 
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of development depending on brain region (Schambra et al., 1994). For example, 
in most brain areas D2-like receptor mRNA increases steadily until adulthood, 
although some studies report a slight decline in the dorsal striatum between 
PD16 and PD28 (Chen & Weiss, 1991; Jung & Bennett, 1996; Srivastava et al., 
1992; Weiss, Chen, Zhang, & Zhou, 1992). In contrast, D2-like receptor mRNA in 
the midbrain peaks by PD14 and then declines to adult levels (Creese et al., 
1992).  
 
D2High Receptors and Measures of D2 Functionality  
 Evidence suggests that there are ontogenetic changes in the functional 
state of D2-like receptors. A study by McDougall et al. (2015) assessed the 
number of D2High receptors in preadolescent, adolescent, and adult rats. Their 
results indicated that the percentage of D2High receptors in the dorsal striatum of 
preadolescent rats was twice that of adolescent (PD40) and adult (PD80) rats, 
although there were no differences in the percentage of D2High receptors between 
the various preadolescent ages (PD5, PD10, PD15, PD20). In an experiment 
particularly important to this thesis, we examined the effects of haloperidol and 
aripiprazole on the dorsal striatal D2High receptors of young rats. Haloperidol and 
aripiprazole was administered via intraperitoneal injection from PD10 through 
PD20. Following either a 4 or 8 day drug abstinence period, dorsal striatal tissue 
was extracted and analyzed via dopamine competition assays using 
[3H]domperidone. Regardless of drug abstinence period, our results indicated 
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that both haloperidol and aripiprazole significantly increased the percentage of 
D2High receptors in the dorsal striatum of preadolescent rats. Thus, these results 
demonstrate that antipsychotic drugs can alter D2High receptors during early 
development as well as in adulthood (Seeman, 2008).  
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CHAPTER FIVE 
EFFECTS OF REPEATED TREATMENT WITH DOPAMINE COMPOUNDS  
ON D2 RECEPTORS 
 
Overview 
Evidence suggests that as many as 70% of people with schizophrenia are 
supersensitive to dopamine agonists, as evidenced by agonist-induced 
exacerbation of psychotic symptomology (Lieberman, Kane, & Alvir, 1987). 
Supersensitivity is not simply due to an increase in the quantity of D2-like 
receptors, but it can be caused by changes in the functional state of the receptor 
(Seeman et al., 2005). Repeated treatment with dopamine antagonists, 
especially first-generation antipsychotics, can cause dopamine receptor 
upregulation (Burt, Creese, & Snyder, 1977; Laruelle et al., 1992; O’Dell et al., 
1990; Wilmot & Szczepanik, 1989). Upregulation is manifested as an increase in 
the number of dopamine receptors, which results from dopamine denervation or 
prolonged pharmacological blockade of dopamine receptors (Ginovart, Wilson, 
Hussey, Houle, & Kapur, 2008; Seeman, Lee, Chau-Wong, & Wong, 1976; 
Staunton, Magistretti, Koob, Shoemaker, & Bloom, 1982). The behavioral impact 
of dopamine receptor upregulation often takes the form of extrapyramidal side 
effects or tardive dyskinesia (Creese & Snyder, 1980; Klawans & Rubovitz, 1972; 
Tarsy & Baldessarini, 1977). Repeated treatment with second-generation 
antipsychotics results in an upregulation of D2-like receptors, but long-term 
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extrapyramidal side effects do not appear as severe. Kapur and Seeman (2014) 
proposed that the lack of side effects may be due to the fast dissociation of these 
compounds at D2-like receptors, although the more favorable treatment outcome 
of second-generation antipsychotics has yet to be fully explained (Dwivedi, 
Rizavi, & Pandey, 2002). The third-generation antipsychotic aripiprazole is 
thought to be more of a “stabilizer” of receptor activity, thus resulting in fewer 
side effects in people with schizophrenia (Kirino, 2012). There is conflicting 
evidence as to whether aripiprazole causes D2-like receptor upregulation in the 
dorsal striatum, since either no changes or slight increases in D2 receptor 
numbers have been reported (Inoue et al., 1997; Tadokoro et al., 2012).  
 
Effects of Repeated Haloperidol or Aripiprazole Treatment on D2-like Receptors 
in the Dorsal Striatum of Adult Rodents 
 
Upregulation of D2-like Receptors 
 It is well established that repeated treatment with haloperidol causes an 
upregulation of D2-like receptors in the dorsal striatum. Following 21 days of 
haloperidol treatment, D2-like receptors in the dorsal striatum increase by 
approximately 50% (O’Dell et al., 1990; Wilmot & Szczepanik, 1989). When 
combined with denervation of dopamine neurons, repeated treatment with 
haloperidol leads to even greater increases in D2-like receptor numbers (Reches, 
Wagner, Jackson, Yablonskaya-Alter, & Fahn, 1983; Shaunton, Magistretti, 
Koob, Shoemaker, & Bloom, 1982). In general, studies comparing the effects of 
repeated haloperidol and aripiprazole treatment conclude that the first-generation 
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antipsychotic is much more likely to induce D2-like receptor upregulation. 
Following repeated administration of haloperidol (1, 2, or 4 mg/kg) or aripiprazole 
(12 or 100 mg/kg) for 21 days, haloperidol caused a 40% increase in dorsal 
striatal D2-like receptors (i.e. Bmax values). In contrast, aripiprazole produces only 
a nonsignificant upregulation of D2 receptors when compared to control values, 
suggesting that aripiprazole acts as an antagonist at dorsal striatal D2 receptors 
regardless of its potency (12 or 100 mg/kg) (Inoue et al., 1997). In a similar 
study, Tadokoro et al. (2012) showed that a 14-day regimen of haloperidol 
caused an upregulation of dorsal striatal D2-like receptors (Bmax = 153% 
increase), while the same regimen of  aripiprazole produced only a slight, 
nonsignificant increase in the density of D2-like receptors (Bmax = 126% 
increase). As with the Inoue et al. (1997) study, the Bmax values of aripiprazole 
and vehicle control groups did not differ. In conclusion, repeated treatment with 
haloperidol increases the number of dorsal striatal D2-like receptors, but the 
impact of repeated aripiprazole treatment on these receptors remains elusive.   
Alterations in the Percentage of D2High Receptors  
 A separate issue is whether repeated treatment with dopamine 
antagonists alters the affinity state of D2-like receptors. This issue is particularly 
important because aripiprazole appears to exert antagonistic effects when D2-
like receptors are in a state of high affinity. In a critical study for this thesis, 
Seeman (2008) reported that repeated treatment with aripiprazole caused a 
significant increase in the percentage of dorsal striatal D2High receptors. Not 
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surprisingly, chronic treatment with haloperidol also results in an elevated 
percentage of D2High receptors (Seeman et al., 2005).  
 In summary, repeated treatment with haloperidol causes a dramatic 
upregulation of D2-like receptors, whereas the effect of repeated aripiprazole 
treatment on D2-like receptor numbers is ambiguous (Inoue et al., 1997; 
Tadokoro et al., 2012). In contrast, repeated treatment with both haloperidol and 
aripiprazole increases the percentage of D2-like receptors in a high affinity state. 
If anything, aripiprazole may increase D2High receptors to a greater extent than 
haloperidol (Seeman et al., 2005); this suggests that repeated aripiprazole 
treatment may cause long-term modifications in behavior by altering D2 affinity 
as opposed to upregulating D2-like receptors.  
Changes in D2 Receptor cAMP and Akt Signaling Pathways  
 Repeated treatment with haloperidol and aripiprazole affects the cAMP 
and Akt signaling pathways. As mentioned in a previous chapter, D2-like receptor 
stimulation activates a Gi protein which decreases adenylyl cyclase activity and, 
as a consequence, reduces cAMP levels and PKA activity (Beaulieu & 
Gainetdinov, 2011; Kebabian & Cote, 1981; Missale et al., 1998). The Akt 
pathway is also modulated by D2-like receptor stimulation. Specifically, D2-like 
receptor activation decreases Akt levels and inhibits GSK-3β activity which, in 
turn, inhibits β-catenin (Freyberg, Ferrando, & Javitch, 2010; Li & Gao, 2011). 
Importantly, GSK-3β is a critical component regulating hyperdopaminergic 
behaviors, since decreased activity in this pathway is associated with 
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hyperdopaminergic conditions (Li & Gao, 2011; Li, Xi, Roman, Huang, & Gao, 
2009).  
 D2-like receptor blockade increases activity within the cAMP pathway. For 
example, chronic treatment with haloperidol increases adenylyl cyclase activity 
(Iwatsubo & Clouet, 1975). In vitro studies show a pronounced increase in cAMP 
following exposure to haloperidol, and lesser increases in cAMP levels after 
treatment with second-generation antipsychotics (Masri et al., 2008). Curiously, 
aripiprazole decreases cAMP levels in vitro (Masri et al., 2008). Chronic 
treatment with haloperidol increases PKA activity in the dorsal striatum, while 
other evidence suggests that acute haloperidol treatment may also result in 
phosphorylation of PKA (Pan, Chen, Lian, Huang, & Deng, 2015; Turalba, Leite-
Morris, & Kaplan, 2004). Acute treatment with aripiprazole did not produce a 
significant change in the amount of phosphorylated PKA (Pan et al., 2015).      
 The Akt pathway is also affected by repeated treatment with dopaminergic 
compounds (Alimohamad, Rajakumar, Seah, & Rushlow, 2005). For example, a 
long-term regimen of haloperidol significantly increased phosphorylated Akt 
levels in the dorsal striatum of both rats and mice (Emamian, Hall, Birnbaum, 
Karayiorgou, & Gogos, 2004; Sutton & Rushlow, 2011); however, the acute 
effects of haloperidol treatment on phosphorylated Akt remain unclear, since 
there are conflicting reports that haloperidol either increases phosphorylated Akt 
levels (Emamian et al., 2004) or has no effect (Pan et al., 2015). Acute 
aripiprazole treatment had somewhat different actions, as acute treatment with 
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aripiprazole produced only a nonsignificant increase in phosphorylated Akt levels 
(Pan et al., 2015).  
 Other proteins within the Akt pathway are also altered after treatment with 
antipsychotics. Repeated treatment with a moderate dose of haloperidol 
increased both GSK-3β and β-catenin levels in dorsal striatal tissue (Alimohamad 
et al., 2005). Within the dorsal striatum, increased GSK-3β labeling was 
observed in cell bodies and nearby dendrites, whereas increased β-catenin 
labeling occurred more densely in nuclear or neuropil areas. Elevated levels of 
GSK-3β and β-catenin were also found in deeper layers of the prefrontal cortex, 
which coincides with the location of D2-like receptors (Alimohamad et al., 2005; 
Berendse, Galis-de Graaf, & Groenewegen, 1992; Larson & Ariano, 1995). Acute 
haloperidol treatment did not alter GSK-3β or β-catenin levels (Pan et al., 2015); 
however, a single injection of aripiprazole did increase phosphorylated GSK-3β 
(Pan et al., 2015).  
 In summary, these results indicate that repeated treatment with 
haloperidol or aripiprazole affects the cAMP and Akt signaling pathways of adult 
rats, although the effects of haloperidol are generally more pronounced. 
Regarding the cAMP pathway, both acute and repeated treatment with 
haloperidol increased PKA catalytic activity (Dwivedi et al., 2002; Pan et al., 
2015). There is a lack of evidence regarding the effects of repeated aripiprazole 
treatment on phosphorylated PKA, but acute aripiprazole did increase the alpha 
PKA catalytic subunit with no significant increase in the ratio of p-PKA to PKA 
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(Pan et al., 2015). Within the Akt pathway, repeated haloperidol treatment lead to 
increases in phosphorylated Akt, GSK-3β, and β-catenin (Alimohamad et al., 
2005; Emamian et al., 2004; Sutton & Rushlow, 2011). In acute models, there is 
conflicting evidence regarding the effects of haloperidol on phosphorylated Akt 
levels, but studies consistently find that haloperidol does not increase the amount 
of phosphorylated GSK-3β (Emamian et al., 2004; Pan et al., 2015; Sutton & 
Rushlow, 2011). On the other hand, the effects of repeated aripiprazole 
treatment on the Akt pathway are unknown. That being said, acute aripiprazole 
administration did increase the amount of phosphorylated GSK-3β and, perhaps, 
phosphorylated Akt (Pan et al., 2015).  
 
Effects of Repeated Treatment of Haloperidol and Aripiprazole on D2-like 
Receptors in the Dorsal Striatum of Young Rodents 
 Repeated treatment with haloperidol and aripiprazole in young rats causes 
upregulation of D2-like receptors in the dorsal striatum (Der-Ghazarian, 
Charntikov, Varela, Crawford, McDougall, 2010). Similar to adult rodents, 
haloperidol appears to produce greater D2-like receptor upregulation than 
aripiprazole (Der-Ghazarian et al., 2010). To date, no studies have investigated 
the acute or chronic effects of haloperidol or aripiprazole on the cAMP or Akt 
second messenger systems of young rats.  
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CHAPTER SIX 
THESIS STATEMENT 
 
Conclusion 
 Despite the effectiveness of first-generation antipsychotics in reducing 
positive symptoms, extrapyramidal side effects remain a major problem when 
treating schizophrenia. Therefore, there is a need for an effective 
pharmacotherapy with fewer side effects, such as aripiprazole. The ability of 
repeated aripiprazole treatment to mitigate psychosis has been demonstrated, 
although relatively little is known about its mechanism of action. Aripiprazole is 
frequently prescribed to children and adolescents because of its low side effect 
profile (Kirino, 2012; Masi et al., 2009; Stachnik & Nunn-Thompson, 2007; Yoo et 
al., 2011); however, few preclinical studies have examined the neural effects of 
aripiprazole in young populations. For this reason, more information is needed 
regarding the effects of repeated aripiprazole treatment across ontogeny.  
 Alterations in D2-like receptor functioning are responsible for many of the 
symptoms associated with schizophrenia as well as the extrapyramidal side 
effects that result from dopamine antagonist treatment. For example, D2-like 
agonists induce psychosis and exacerbate psychotic symptoms, whereas D2-like 
receptor antagonists reduce positive symptoms (Li & Gao, 2011; Lieberman et 
al., 1987). In terms of side effects, D2-like agonists alleviate Parkinsonism and 
related motoric disturbances (Li & Gao, 2011). Many years ago, Davis et al. 
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(1991) proposed that schizophrenia is primarily due to dysregulation of dopamine 
systems in the nucleus accumbens and prefrontal cortex. More recently, Seeman 
(2011) has extended this model by proposing that an excess of D2High receptors 
is responsible for psychosis. Although research examining the effects of 
antipsychotic drugs on the D2High receptors of adult rats is well along (Seeman, 
2008), it is important to determine the effects of repeated haloperidol and 
aripiprazole treatment on the percentage of D2High receptors in young rats.  
 Traditionally, it is understood that repeated treatment with first-generation 
antipsychotics lessens psychosis through antagonism of D2-like receptors, which 
has the unwanted side effect of upregulating these receptors. Despite symptom 
reduction, first-generation antipsychotics cause more extrapyramidal side effects 
than second- or third-generation antipsychotics (Croxtall, 2012; Leucht et al., 
2009). As an example, repeated treatment with haloperidol results in an 
upregulation of D2-like receptors, a larger percentage of D2High receptors, and 
behavioral supersensitivity (Inoue et al., 1997; Seeman et al., 2005; Tadokoro et 
al., 2012; Varela et al., 2014). In contrast, treatment with the third-generation 
antipsychotic aripiprazole results in a slight, nonsignificant upregulation of D2-like 
receptors, an increased percentage of D2High receptors, and relatively less 
supersensitivity (Seeman, 2008; Tadokoro et al., 2012; Varela et al., 2014). The 
lack of pronounced D2-like receptor upregulation suggests that aripiprazole does 
not operate under the traditionally understood mechanisms of first-generation 
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antipsychotics, although both haloperidol and aripiprazole do increase the 
percentage of D2High receptors (Seeman, 2008).  
 Since dopamine system dysfunction is a hallmark of schizophrenia, it is 
not surprising that second messenger systems associated with D2-like receptors 
are often dysregulated in schizophrenia. Indeed, some researchers speculate 
that dysfunction involving the cAMP and Akt pathways may be a critical neural 
mechanism underlying schizophrenia (Beaulieu, Del’Guidice, Sotnikova, 
Lemasson, & Gainetdinov, 2011; Emamian et al., 2004; Karam et al., 2010; 
Lovestone, Killick, Di Forti, & Murray, 2007). For example, Li et al. (2009) have 
hypothesized that GSK-3β, a component of the Akt pathway, may modulate 
dopamine-dependent behaviors by inhibiting NMDA receptors in the prefrontal 
cortex. Thus, hyperdopaminergic behaviors may be a consequence of GSK-3β 
attenuating glutamatergic functioning (Li et al., 2009). Regardless of the exact 
explanation, it is clear that PKA, Akt, and GSK-3β are dysregulated in the frontal 
cortex of schizophrenics (Emamian et al., 2004).  
 Consistent with the latter findings, repeated and acute treatment with 
antipsychotic drugs alters the functioning of the cAMP and Akt pathways. Within 
the dorsal striatum of adult rats, repeated haloperidol treatment increases 
phosphorylated PKA, Akt, GSK-3β, and β-catenin (Alimohamad et al., 2005; 
Dwivedi et al., 2002; Emamian et al., 2004; Sutton & Rushlow, 2011). In contrast, 
there is a general lack of information regarding the effects of repeated 
aripiprazole treatment on the cAMP and Akt pathways. The only available 
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evidence suggests that acute treatment with aripiprazole slightly enhances the 
phosphorylation of GSK-3β and possibly Akt (Pan et al., 2015).  
 In addition to possibly being involved in the manifestation of 
schizophrenia, alterations of the cAMP and Akt pathways may be responsible for 
some of the side effects (e.g. extrapyramidal effects) associated with 
antipsychotic drugs. In other words, D2-like receptor antagonists may produce 
side effects by causing persistent change in the cAMP and/or Akt second 
messenger systems through actions at D2-like receptors. Based on the evidence 
presented above, it is possible that aripiprazole has a lesser impact on these 
second messenger systems, thereby resulting in fewer side effects. Consistent 
with this idea, repeated aripiprazole treatment causes relatively less behavioral 
supersensitivity in young rats than does haloperidol (Varela et al., 2014). 
 This thesis examined the effects of repeated aripiprazole and haloperidol 
treatment on dopamine systems in the dorsal striatum of preadolescent and adult 
rats.  We previously reported that repeated haloperidol and aripiprazole 
treatment increased the percentage of D2High receptors in young rats; however, 
we did not assess whether these changes had any functional consequence. 
Therefore, I examined the functionality of D2-like receptors by conducting GTPγS 
assays and measuring the cAMP and Akt second messenger systems, after 
repeated exposure to haloperidol or aripiprazole. My expectation was that 
aripiprazole and haloperidol would increase the efficacy of D2-like receptors as 
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measured by the GTPγS assay. These D2-like receptor changes, in turn, were 
predicted to cause enhanced responsiveness in the cAMP and Akt pathways.  
 
Proposed Hypotheses 
 In my first experiment, [35S]GTPγS binding assays were conducted to 
assess the effects of repeated haloperidol and aripiprazole treatment on the 
efficacy of D2-like receptors (i.e. the coupling of Giα to D2 receptors). 
Preadolescent and adult rats were pretreated with haloperidol or aripiprazole for 
11 consecutive days. After either a 4 or 8 day drug abstinence period, rats were 
euthanized and dorsal striatal tissue dissected out and stored until assay. Based 
on the previously gathered D2High data, I hypothesized that the D2-like receptors 
of younger rats would show a greater efficacy than adult rats. I did not expect 
that the different drug abstinence periods would affect GTPγS binding. I also 
hypothesized that the D2-like receptors of haloperidol-treated rats would display 
greater efficacy than aripiprazole-treated groups, and that D2-like receptors of 
both drug groups would demonstrate greater efficacy than those treated with 
saline.  
 In my second experiment, I assessed the cAMP second messenger 
system. More specifically, I measured PKA subunits (i.e. alpha and beta catalytic 
subunits, regulatory subunits, and phosphorylated PKA) in order to determine if 
upregulation of any of these subunits occurred after repeated haloperidol or 
aripiprazole treatment. Preadolescent and adult rats were repeatedly 
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administered haloperidol, aripiprazole, or vehicle for 11 days, and dorsal striatal 
tissue was extracted after a 4 or 8 day drug abstinence period. Levels of PKA 
subunits in the dorsal striatum was measured using Western Blot analysis. I 
hypothesized that there would be greater increases in the amount of 
phosphorylated PKA in younger rats compared to adult rats, but no differences 
due to the 4 or 8 day drug abstinence periods. Additionally, I hypothesized that 
there would be increased phosphorylated PKA in haloperidol-treated rats in 
comparison to aripiprazole-treated rats, and that both haloperidol and 
aripiprazole would induce elevated levels of phosphorylated PKA when 
compared to rats that receive vehicle.  
 I also assessed components of the Akt pathway, specifically, the amount 
of phosphorylated Akt relative to nonphosphorylated Akt, and the amount of 
phosphorylated GSK-3β relative to nonphosphorylated GSK-3β. As mentioned 
previously, preadolescent and adult rats received repeated injections of 
haloperidol, aripiprazole, or vehicle for 11 days. Dorsal striatal tissue was 
extracted after a 4 or 8 day drug abstinence period and phosphorylated Akt and 
GSK-3β was measured using Western Blot analysis. I hypothesized that younger 
rats would demonstrate larger increases in phosphorylated Akt and GSK-3β 
levels than adult rats, and that there would be no differences between the 4 or 8 
day drug abstinence periods. I also hypothesized that rats treated with 
haloperidol and aripiprazole would display elevated amounts of phosphorylated 
Akt and GSK-3β relative to rats that receive vehicle.  
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CHAPTER SEVEN 
METHODS 
 
Subjects 
 Subjects were 164 male and female Sprague-Dawley rats (Charles River 
Laboratories, Hollister, CA, USA). Eighty subjects were preadolescent rats born 
and raised at California State University, San Bernardino (CSUSB). 
Preadolescent rats were culled to 10 pups per litter by PD3 and housed with the 
dam in the same cage. Eighty-four adult subjects were purchased from Charles 
River Laboratories and arrived on PD51-59. Approximately equal numbers of 
male and female rats were assigned to all conditions. 
 The colony room was maintained at a temperature of 22-24°C and was 
kept under a 12 hour light/dark cycle. Drug administration was conducted during 
the light cycle. Food and water were available at all times. All subjects were 
treated according to the “Guide for the Care and Use of Mammals in 
Neuroscience and Behavioral Research” (National Research Council, 2003) and 
the research protocol was approved by the Institutional Animal Care and Use 
Committee at CSUSB.  
 
Drugs 
 Haloperidol was dissolved in saline, whereas aripiprazole was dissolved in 
(2-hydropropyl)-β-cyclodextrin (HBC) solution. Saline served as the control 
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vehicle for haloperidol, and HBC served as the control vehicle for aripiprazole. 
Drugs were injected at a volume of 2.5 ml/kg for preadolescent rats and 2 ml/kg 
for adults.  
 
Design 
These experiments used 2 x 2 x 3 between-subjects experimental designs 
(Subject Age: young vs. adult; Drug Type: haloperidol vs. aripiprazole vs. 
saline/HBC; Drug Abstinence Period: 4 or 8 days). A drug abstinence period of 
either 4 or 8 days was chosen because these durations are commonly used for 
adult rats, although there is a dearth of evidence regarding an ideal drug 
abstinence period for young rats. Similar drug abstinence periods were used to 
assess the effects of repeated aripiprazole and haloperidol treatment on the 
dorsal striatum of early adolescent rats (Varela et al., 2014).  
D2 receptor function was measured using GTPγS assays and Western 
Blots. Specifically, the GTPγS assay measured the coupling of Giα to D2 
receptors and the Western Blots assessed Akt, GSK-3β, and PKA subunit levels. 
Male and female rats were included in the study, with sex differences analyzed 
separately from the previously mentioned statistical analyses.  
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Procedures 
Pretreatment Phase 
Young rats began injections at PD10, while adult rats began injections at 
PD80. Haloperidol (1 mg/kg), aripiprazole (10 mg/kg), and vehicle (saline/HBC), 
were administered for 11 days: postnatal day PD10 through PD20 for young rats 
and PD70 through PD80 for adult rats. Injections were followed by a drug 
abstinence period of either 4 or 8 days. Subjects were then sacrificed by rapid 
decapitation (PD24 or PD28 for juveniles and PD84 or PD88 for adults). Dorsal 
striatal tissue was dissected out and kept at -80 °C until assay.  
 [S35]GTPyS Binding Assay  
On the day of assay, tissue was thawed and homogenized in 100 volumes 
of 50 mM Tris–HCl buffer (pH 7.4) for approximately 20 s using a Brinkman 
Polytron. Homogenates were centrifuged at 20 000 × g for 30 min. The pellet was 
then resuspended in 100 volumes of the same buffer and centrifuged again at 20 
000 × g for 30 min. The final pellet was suspended in approximately 20 volumes 
of buffer (pH 7.4) and incubated for 30 min at 37 °C to remove endogenous 
transmitter.  
[35S]GTPγS binding was conducted in duplicate tubes in assay buffer (50 
mM Tris–HCl, 120 mM NaCl) containing 30 μM GDP, 10–20 μg protein, and 
dopamine in various concentrations. Nonspecific binding was determined in the 
presence of 30 μM cold GTPγS. The tubes were preincubated for 15 min at 37 
°C, after which 0.1 nM [35S]GTPγS were added. Following the addition of 
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[35S]GTPγS, tubes were incubated for an additional 45 min at 37 °C. The 
incubation period was terminated by filtering the contents of the tubes using 
glass fiber filters. Net agonist-stimulated [35S]GTPγS binding values were 
calculated by subtracting basal binding values (without agonist) from agonist-
stimulated values (with agonist) and dividing by basal values. Agonist potency 
(pEC50) and agonist efficacy (Emax) were determined by iterative nonlinear 
regression fitting using Prism (Graph Pad Software).  
Western Blot Analyses for PKA and Akt 
 The levels of Akt/p-Akt, GSK-3β/p-GSK-3β, and PKA/p-PKA were 
determined using Western Blotting. Four different proteins were used to assess 
PKA: the alpha catalytic subunit (PKA-Cα), the beta catalytic subunit (PKA-Cβ), 
the regulatory subunit (PKA-RII), and p-PKA. Briefly, dorsal striatal samples 
(20 µg protein) were mixed with lamemmeli buffer, boiled for 5 min at 95 °C, and 
loaded on 12% polyacrylamide gels. Homogenates were then transferred to 
polyvinylidene fluoride (PVDF) membranes. Membranes were rinsed in TBST 
buffer (20 mM Tris-HCl, 150 mM NaCl, and 0.5% Tween20) and then blocked 
with 5% non-fat milk in TBST (diluted in blotto) for 2 h. Membranes were then 
incubated with the primary rabbit antibody for Akt [1:20,000 (diluted in blotto); 
#C67E7], phospho-Akt [Thr308; 1:10,0000 (diluted in blotto); Cell Signaling 
Technology, #D25E6], PKA-Cβ [1:10,000 (diluted in blotto); Santa Cruz 
Biotechnology, #SC-904], or p-PKA [Thr197; 1:50,000 (diluted in blotto); Cell 
Signaling Technology, #5661] overnight at 4 C. The next day, the blots were 
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washed five times with TBST for 5 min each and then incubated in anti-rabbit 
IgG-HRP secondary antibody [1:50,000 (diluted in blotto); Santa Cruz 
Biotechnology] 2 h at room temperature. After membranes were washed five 
times in TBST, immunoreactive proteins were revealed with enhanced 
chemiluminescence (Thermo Fisher SuperSignal West Dura Extended Duration 
Substrate, Thermo Fisher Scientific). Immunoreactive bands were then visualized 
and quantified using a computer-assisted digital imagining program (Chemi-Doc, 
Bio-Rad). Following quantification, blots were mildly striped with a commercially 
available buffer (Restore Western Blot Stripping Buffer, Thermo Fisher 
Scientific), and the blotting procedure was redone using primary rabbit antibodies 
for GSK-3 α/β [1:20,000 (diluted in blotto); Cell Signaling, #D75D3], phospho-
GSK-3β [Ser9; 1:20,000 (diluted in blotto); Cell Signaling Technology, #D3A4], 
PKA-RII [1:10,000 (diluted in blotto); Santa Cruz Biotechnology, #SC-908], and 
PKA-Cα [1:75,000 (diluted in blotto); Cell Signaling Technology, #5842].  
 
Data Analyses  
 Data were initially analyzed using four-way ANOVAs (Age x Drug x 
Abstinence Period x Sex) for the GTPγS and Western Blot experiments. Sex was 
excluded as a factor in the final statistical analyses if the main effect and 
interactions involving the sex independent variable were nonsignificant. Tukey 
tests (p<.05) were used for making planned and post hoc comparisons. Litter 
47 
 
effects were controlled by assigning no more than one subject from each litter to 
a particular group (for a fuller discussion of litter effects, see Zorrilla, 1997).   
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CHAPTER EIGHT 
RESULTS 
 
Experiment 1 
GTPγS Binding  
 Repeated treatment with haloperidol or aripiprazole did not significantly 
affect D2-like receptor efficacy (i.e. Emax values) in young or adult rats (see Table 
1) [Drug x Age interaction, F(2,60) = .68, p = .51]. Likewise, neither haloperidol or 
aripiprazole altered the potency (i.e. pEC50 values) of NPA-stimulated 
[35S]GTPγS specific binding in either age group [Drug x Age interaction, F(2,60) 
= 1.43, p = .25]. D2 receptor efficacy and potency were not differentially affected 
by the drug abstinence period [F(1,60) = .34, p = .56; F(1,60) = .044, p = .835].  
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Table 1. Mean D2 Receptor Efficacy and Potency (Emax and pEC50, respectively) 
in the Dorsal Striatum of Young (PD24 and PD28) and Adult (PD84 and PD88) 
Rats.  
Drug Emax  pEC50  
  
Young 
 
Adult 
 
Young 
 
Adult 
 
Vehicle 
 
27.08 (+3.89) 
 
32.96 (+4.27) 
 
6.35 (+0.26) 
 
6.23 (+0.31) 
 
Aripiprazole
  
 
20.61 (+2.66) 
  
 
30.15 (+3.02) 
 
7.14 (+0.30) 
 
6.47 (+0.32) 
 
Haloperidol 
 
27.17 (+2.47) 
 
28.92 (+3.75) 
 
6.46 (+0.29) 
 
6.78 (+0.23) 
Note: Emax (mean, +SEM) is expressed as fmol/mg weight wet tissue; pEC50 
(mean, +SEM) is the log of EC50 (nm) 
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Experiment 2 
Western Blots  
 In both age groups, haloperidol significantly increased the expression of 
dorsal striatal PKA-Cα (122.82% ± 7.2), PKA-Cβ (115.98% ± 5.6), and PKA-RII 
(122.30% ± 6.3), but not p-PKA (see Tables 2 and 3) [Drug main effect, F(2,84) = 
5.30, p = 0.007; F(2,84) = 5.04, p = 0.009; and F(2,84) = 6.08, p = 0.003, 
respectively]. Haloperidol also significantly increased PKA-Cβ and PKA-RII levels 
relative to aripiprazole (96.87% ± 5.1 and 105.26% ± 5.4, respectively). After 4 
abstinence days, PKA-Cα and PKA-RII levels were higher in young rats than 
adult rats (see Figures 1 and 2) [Age x Drug Abstinence Period interaction, 
F(1,84) = 6.15, p = .015; and F(1,84) = 7.25, p = .009, respectively]. Adult rats 
had higher levels of both proteins when assessed after 8 rather than 4 
abstinence days. No significant main effects or interactions involving the sex 
independent variable were apparent.  
 
 
 
 
 
 
 
 
 
 
51 
 
 
Table 2. Mean Dorsal Striatal PKA-Cα and PKA-Cβ Values of Young (PD24 and 
PD28) and Adult (PD84 and PD88) Rats.  
Drug PKA-Cα  PKA-Cβ  
  
Young 
 
Adult 
 
Young 
 
Adult 
 
Vehicle 
 
100  
 
100  
 
100  
 
100 
 
Aripiprazole
  
 
120.26 (+8.9) 
  
 
110.33 (+6.1) 
 
99.98 (+8.0) 
 
93.75 (+6.6) 
 
Haloperidol 
 
127.52 (+11.9)* 
 
118.12 (+8.4)* 
 
119.07 (+8.1)*† 
 
112.89 (+8.0)* † 
Note: PKA-Cα and PKA-Cβ values (mean, +SEM) are expressed as percent of 
same-aged vehicle controls.  
*Significantly different from rats administered vehicle (saline/HBC) 
†Significantly different from rats administered aripiprazole  
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Table 3. Mean Dorsal Striatal PKA-RII and p-PKA values of Young (PD24 and 
PD28) and Adult (PD84 and PD88) Rats.  
Drug PKA-RII  p-PKA  
  
Young 
 
Adult 
 
Young 
 
Adult 
 
Vehicle 
 
100  
 
100  
 
100 
 
100  
 
Aripiprazole
  
 
107.99 (+7.2) 
  
 
102.52 (+8.4) 
 
121.06 (+11.5) 
 
106.75 (+8.2) 
 
Haloperidol 
 
122.64 (+8.6)* † 
 
121.97 (+9.4)* † 
 
116.13 (+9.1) 
 
116.78 (+11.6) 
Note: PKA-RII and p-PKA values (mean, +SEM) are expressed as percent of 
same-aged vehicle controls.  
*Significantly different from rats administered vehicle (saline/HBC) 
†Significantly different from rats administered aripiprazole  
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Figure 1. Mean percent (+SEM) PKA-Cα levels of young and adult rats after four 
or eight drug abstinence days. 
*Significantly different from adult rats tested after 8 abstinence days 
†Significantly different from young rats tested after 4 abstinence days 
 
 
 
 
 
* † 
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Figure 2. Mean percent (+SEM) PKA-RII levels of young and adult rats after four 
or eight drug abstinence days. 
*Significantly different from adult rats tested after 8 abstinence days 
†Significantly different from young rats tested after 4 abstinence days 
 
 
 
 
 
 
 
* † 
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 Repeated administration of haloperidol significantly increased p-GSK-3β 
levels in the dorsal striatum of young and adult rats (see Table 4) [Drug main 
effect, F(2,84) = 4.96, p = .009], but neither haloperidol nor aripiprazole 
significantly affected GSK-3β, Akt, or p-Akt levels (see Tables 4 and 5). A 
significant Age x Drug Abstinence Period interaction was found [F(1,84) = 6.90, p 
= .01], as Akt levels were elevated in PD24 rats when compared to PD84 rats 
(see Figure 3). Among adult rats, Akt levels were greater after 8 abstinence days 
than at 4 days. No significant main effects or interactions involving the sex 
independent variable were apparent.  
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Table 4. Mean Dorsal Striatal GSK-3β and p-GSK-3β Values of Young (PD24 
and PD28) and Adult (PD84 and PD88) Rats.  
Drug GSK-3β  p-GSK-3β  
  
Young 
 
Adult 
 
Young 
 
Adult 
 
Vehicle 
 
100  
 
100  
 
100 
 
100  
 
Aripiprazole
  
 
102.09 (+11.0)
   
 
119.86 (+19.0) 
 
90.35 (+10.6) 
 
134.19 (+15.4) 
 
Haloperidol 
 
128.11 (+11.1) 
 
109.61 (+11.0) 
 
148.12 (+25.6)* 
 
140.00 (+16.8)* 
Note: GSK-3β and p-GSK-3β values (mean, +SEM) are expressed as percent of 
same-aged vehicle controls.  
*Significantly different from rats administered vehicle (saline/HBC) 
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Table 5. Mean Dorsal Striatal Akt and p-Akt Values of Young (PD24 and PD28) 
and Adult (PD84 and PD88) Rats.  
Drug Akt  p-Akt  
  
Young 
 
Adult 
 
Young 
 
Adult 
 
Vehicle 
 
100  
 
100  
 
100  
 
100 
 
Aripiprazole
  
 
105.04 (+5.8) 
  
 
108.97 (+8.7) 
 
119.2 (+14.2) 
 
135.21 (+19.6) 
 
Haloperidol 
 
108.74 (+4.9) 
 
100.88 (+8.6) 
 
140.69 (+19.8) 
 
123.65 (+15.9) 
Note: Akt and p-Akt values (mean, +SEM) are expressed as percent of same-
aged vehicle controls. 
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Figure 3. Mean percent (+SEM) Akt levels of young and adult rats after four or 
eight drug abstinence days. 
*Significantly different from adult rats tested after 8 abstinence days 
†Significantly different from young rats tested after 4 abstinence days 
 
 
 
 
 
 
 
 
 
* † 
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CHAPTER NINE 
DISCUSSION 
 
 Schizophrenia is a disorder that can affect humans across the life-span, 
and a variety of factors are thought to initiate its onset throughout maturation. 
Although first-, second-, and third-generation antipsychotics reduce positive 
symptoms, this is often at the cost of persisting extrapyramidal effects (Croxtall, 
2012; Leucht et al., 2009; Mailman & Murthy, 2010). These undesirable effects 
are likely the result of an excessive number of D2 receptors in the dorsal striatum 
(Inoue et al., 1997; Schröder, Bubeck, & Sauer, 2000, Silvestri et al., 2000; 
Varela et al., 2014). Consistent with this explanation, repeated treatment with 
haloperidol and aripiprazole causes long-term increases in dorsal striatal D2High 
receptors in young rats, as well as adults (Seeman, 2008). Importantly, the 
ramifications of these receptor changes on D2 second messenger systems have 
not previously been determined. Specifically, it is unclear whether drug-induced 
changes in the percentage of D2High receptors affect the functioning of 
downstream signaling pathways. In an effort to examine this idea, I sought to 
determine whether repeated haloperidol or aripiprazole treatment would alter the 
efficacy of D2 receptors and/or impact the cAMP and Akt signaling pathways. 
Both young and adult rats were included in this study since (1) haloperidol and 
aripiprazole are commonly prescribed to humans across ontogeny, and (2) young 
rats possess a higher percentage of D2High receptors than adults.  
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 Development has emerged as an important factor when assessing D2 
receptor function. Dorsal striatal D2 receptors appear to function differently 
across development, as young rats possess a greater percentage of D2High 
receptors than adolescent or adult rats (McDougall et al., 2015). Because of this 
finding, the current study focused on the effects of chronic aripiprazole treatment 
on the dorsal striatum during development. For example, we previously 
demonstrated an increase in the percentage of D2High receptors in the dorsal 
striatum of young rats following repeated haloperidol and aripiprazole treatment. 
Whether these receptor changes have functional implications is unknown. To 
assess functionality, I measured the long-term effects of haloperidol and 
aripiprazole on GTPγS binding, as well as D2 signaling mechanisms. 
 
Effects of Repeated Haloperidol and Aripiprazole Treatment on D2 Receptor 
Efficacy and Potency 
 
 The GTPγS assay is used to determine the efficacy or functionality of D2 
receptors (Harrison & Traynor, 2003; Milligan, 2003). Because young rats have a 
greater percentage of D2High receptors than adults (McDougall et al., 2015), I 
hypothesized that the D2 receptors of young rats, when compared to adults, 
would have greater efficacy. Following either a 4- or 8-day drug abstinence 
period, haloperidol-treated rats were predicted to display more efficacious 
receptors than aripiprazole-treated rats, while rats in both treatment groups were 
predicted to show enhanced D2 receptor efficacy relative to control rats. In 
contrast to original expectations, D2 receptor efficacy did not significantly change 
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following repeated haloperidol or aripiprazole treatment. In fact, D2 receptor 
efficacy did not differ between young and adult rats, drug groups, drug 
abstinence periods, nor sexes. Likewise, potency (pEC50) did not differ according 
to age, drug, abstinence period, or sex. These results are contrary to original 
expectations. One possibility is that drug-induced increases in the percentage of 
D2High receptors are independent of changes in D2 receptor efficacy. 
Alternatively, D2 receptors in the high affinity state may not initiate changes in 
the cAMP system through traditionally understood mechanisms (i.e. the 
dissociation of Giα from the βγ complex). This possibility suggests that the effects 
of increased D2High receptors are independent of the activation of the cAMP 
signaling cascade. Thus, PKA subunits may upregulate independently of 
changes in D2/Gia coupling, and alternate D2 receptor signaling pathways may 
be responsible for changes in the cAMP system.  
 
Effects of Repeated Haloperidol and Aripiprazole Treatment on the cAMP 
Pathway 
 
 Although haloperidol and aripiprazole did not alter the dissociation of Gia 
from the βy complex, it remains possible that alterations in the percentage of 
D2High receptors might affect downstream proteins within the cAMP pathway. I 
previously hypothesized that young rats would display greater increases in p-
PKA relative to adult rats, and that haloperidol treatment would lead to greater 
elevations of p-PKA than aripiprazole. Interestingly, repeated haloperidol 
treatment did not alter p-PKA, but it did increase the amount of PKA-Cα, PKA-
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Cβ, and PKA-RII relative to vehicle controls. The PKA-Cβ and PKA-RII levels of 
haloperidol-treated rats were also significantly greater than the aripiprazole-
treated groups. No differences were found between age groups, sex, nor drug 
abstinence period. The increases in PKA subunits may be attributed to the 
general upregulation of D2 receptors after repeated haloperidol treatment. 
Interestingly, since haloperidol and aripiprazole both increase the percentage of 
D2High receptors, it is likely that this factor cannot solely account for the changes 
in the cAMP pathway after haloperidol treatment. On the contrary, since D2 
receptors do not cause long-term changes in the quantity of PKA subunits after 
aripiprazole treatment, perhaps the unique actions of aripiprazole as a partial 
agonist allow for an increase in D2High receptors without lasting effects on the 
cAMP pathway. This pattern of results preserves the possibility that increased 
levels of PKA are linked to some of the more lasting actions of haloperidol, such 
as extrapyramidal effects. 
 Using a different model, Pan and colleagues have attempted to determine 
the short-term effects of haloperidol and aripiprazole treatment on PKA subunits. 
However, a critical distinction must be made in comparing the methods of Pan et 
al. (2015, 2016a, 2016b) to the present study. Notably, the work of Pan et al. 
(2015, 2016a, 2016b) assessed the short-term effects of haloperidol and 
aripiprazole treatment on second messenger components, while this thesis 
focused on the long-term effects of these drugs on D2 second messenger 
systems after 4- or 8-day drug abstinence period. Thereby, the interpretation of 
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Pan et al. (2015, 2016a, 2016b) is centered on the effects of haloperidol and 
aripiprazole shortly after the conclusion of drug treatment; whereas, the current 
study is concerned with long-term, potentially permanent changes in receptor 
function after repeated drug treatment. Pan et al. (2015, 2016b) reported 
increased levels of PKA-Cα after both a 1- and 7-day haloperidol and aripiprazole 
treatment regimen. p-PKA was also increased after a 7-day regimen of 
haloperidol but not aripiprazole (Pan et al., 2016b). Though this evidence 
suggests that aripiprazole exerts less intense effects on the cAMP system when 
compared to haloperidol, the present results also highlight the importance of the 
drug abstinence period when considering the effects of drug-induced receptor 
changes on the cAMP system. 
 The current study demonstrated increases in PKA subunits after repeated 
haloperidol treatment, which was unlike effects occurring after aripiprazole 
treatment. Specifically, upregulation of PKA subunits (i.e., PKA-Cα, PKA-Cβ, and 
PKA-RII) was present 4 and 8 days after cessation of repeated haloperidol 
treatment, whereas upregulation of the PKA system was not apparent following 
repeated aripiprazole treatment. In terms of haloperidol, it is likely that the 
increase in regulatory subunits (PKA-RII) was in direct response to increases in 
catalytic activity. This effect was not observed when using an acute treatment 
model, as Pan et al. (2015) reported decreased PKA-RII levels after a single 
injection of haloperidol. It is clear that both haloperidol and aripiprazole cause 
acute, short-term activation of the cAMP system (Pan et al., 2015); whereas, the 
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present thesis indicates that haloperidol has more long-lasting effects on the 
cAMP system than aripiprazole. One possibility is that the antagonistic actions of 
haloperidol are more pronounced than those of aripiprazole, thus causing more 
long-term effects. It is also possible that the partial agonist properties of 
aripiprazole “soften” its upregulation of the cAMP system following the conclusion 
of treatment. The lack of phosphorylation observed in the current study may also 
provide insight about the long-term changes in the cAMP system after 
haloperidol and aripiprazole treatment. Interestingly, the lack of p-PKA observed 
in our chronic model could actually indicate increased PKA activity, since 
phosphorylation of PKA can mute some activity of the kinase (Yu et al., 2013). 
Regardless, the present results are consistent with the idea that some of the 
behavioral differences observed after repeated haloperidol and aripiprazole 
treatment may be due to upregulation in the cAMP system.  
 
Effects of Repeated Haloperidol and Aripiprazole Treatment on the Akt Pathway 
 As previously mentioned, the Akt pathway may also play a critical role in 
the therapeutic effects of aripiprazole, and the activity of proteins in this pathway 
may even explain its low side effect profile (Pan et al., 2015). Since increases in 
p-GSK-3β have been demonstrated in a short-term model, in which dorsal striatal 
tissue was assessed 24 hrs following repeated haloperidol treatment (Pan et al., 
2016a), I hypothesized that haloperidol would also increase the p-GSK-3β and p-
Akt levels of adult rats when measured 4 and 8 days after drug discontinuation. 
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Young rats were hypothesized to exhibit an even greater increase in p-GSK-3β 
and p-Akt. The present results showed that haloperidol increased the amount of 
p-GSK-3β, but not p-Akt, in both age groups.  Aripiprazole caused a somewhat 
different pattern of effects, as the partial agonist did not alter p-GSK-3β nor p-Akt 
in either young or adult rats. Similar to the cAMP pathway, haloperidol has a 
lasting impact on the Akt pathway, whereas aripiprazole does not. The differential 
actions of these two compounds on p-GSK-3β levels may be due to the partial 
agonist actions of aripiprazole. It is noteworthy that haloperidol and aripiprazole 
affect other neurotransmitter systems (e.g., serotonergic, adrenergic, GABAergic, 
glutamatergic, etc.) to differing extents, so it is also possible that the generally 
more muted effects of aripiprazole may be a consequence of complex interplay 
of many neurotransmitter systems.  
 The present results show that long-term models, in which neural effects 
are measured 4 or 8 days after drug discontinuation, produce a very different 
pattern of effects than short-term models. For example, we found that p-GSK-3β 
signaling was elevated both 4 and 8 days after cessation of a 10-day haloperidol 
regimen. In contrast, after a 24 hr drug abstinence period, Pan et al. (2015) 
reported increased p-GSK-3β levels after a single injection of aripiprazole but not 
haloperidol. Additionally, there were no short-term increases in p-GSK-3β after a 
7 day regimen of haloperidol or aripiprazole, but haloperidol did increase Akt 
levels (Pan et al., 2016a). When considered together with the cAMP data, the 
results of this thesis and Pan et al. (2015, 2016a, 2016b) indicate the importance 
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of treatment length and drug abstinence period when assessing the effects of 
repeated haloperidol and aripiprazole treatment. Perhaps phosphorylation of 
GSK-3β after aripiprazole treatment provides some beneficial effects, such as 
reduced extrapyramidal effects, but post-treatment phosphorylation of GSK-3β 
may lead to less desirable side effects. Regardless, the consequences of 
haloperidol treatment on p-GSK-3β leave open the possibility that aripiprazole’s 
more favorable side effect profile may be partly due to the differential actions of 
these drugs on the Akt pathway.  
 
Development and the cAMP and Akt Pathways 
 Given its favorable treatment outcomes among humans of various ages, it 
was critical to assess the actions of aripiprazole on D2 receptor systems in both 
young and adult rats. Somewhat surprisingly, the effects of repeated haloperidol 
and aripiprazole treatment did not differ between age groups. This finding has 
interesting implications, for it supports the idea that D2 receptors function 
similarly regardless of age and, therefore, the potential consequences of drug 
action at these receptors is more or less the same. Previous research has 
demonstrated a progressive linear increase in dopamine receptor content from 
prenatal ages through preadolescence, followed by an overabundance of 
receptors during adolescence, and then a decline to adult levels (Andersen, 
Thompson, Rutstein, Hostetter, & Teicher, 2000; Tarazi & Baldessarini, 2000; 
Teicher, Andersen, & Hostetter, 1995. D2High receptors also vary according to 
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age, with young rats having a greater percentage of the high affinity D2 receptors 
than adolescent or adult rats (McDougall et al., 2015). Due to changes observed 
in D2 receptor content and affinity state throughout development, it was plausible 
to hypothesize that the effects of haloperidol and aripiprazole would differ 
according to age. In terms of the Akt and cAMP pathways, at least, our 
hypotheses concerning age-dependent differences were not supported by the 
data. 
 
Drug Abstinence Period 
Drug abstinence period is an important factor to take into account when 
assessing the long-term effects of dopaminergic drugs. If behavioral or neural 
effects are measured shortly after DA antagonist treatment then acute drug 
effects are being examined; however, if assessment occurs days or weeks after 
drug discontinuation then the effects of receptor upregulation are often at issue. 
Haloperidol causes profound D2 receptor upregulation in preweanling and adult 
rats (Der-Ghazarian, Charntikov, Varela, Crawford, & McDougall, 2010; O’Dell et 
al., 1990; Wilmot & Szczepanik, 1989); whereas, repeated aripiprazole treatment 
causes upregulation of D2 receptors in young rats, and may cause slight, non-
significant D2 receptor upregulation in adult rats (Inoue et al., 1997; Tadokoro et 
al., 2012). Thus, differences in upregulation could be responsible for the more 
pronounced actions of haloperidol, relative to aripiprazole, on the cAMP and Akt 
pathways across both age groups. Such an explanation is consistent with the 
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idea that upregulation of D2 receptors is responsible for the extrapyramidal 
effects caused by first-generation antipsychotics (Creese & Snyder, 1980; 
Klawans & Rubovitz, 1972; Tarsy & Baldessarini, 1977).  
In the present study, there were relatively few differences observed 
between the 4- and 8-day drug abstinence periods, but that is probably because 
upregulation was apparent at both time points. Among the differences that were 
observed, young rats, when compared to adult rats, had elevated levels of PKA-
Cα and PKA-RII than adults after 4 abstinence days. In terms of the Akt pathway, 
PD24 rats had higher Akt levels when compared to PD84 rats. In adult rats, Akt 
levels were greater after 8 abstinence days than at 4 days. These findings 
suggest the possibility that adult cAMP and Akt systems display upregulation of 
various proteins well after termination of antipsychotic treatment, and that the 
extent of these changes may be somewhat more pronounced 8 days after drug 
cessation. In this regard, it would be interesting to assess the effects of 
haloperidol and aripiprazole on Akt and cAMP system functioning weeks and 
months after drug discontinuation.    
 
Clinical Relevance 
 Considering the clinical aspects of these findings, it has long been known 
that first-generation antipsychotics cause more extrapyramidal effects than 
second-generation antipsychotics (Croxtall, 2012; Leucht et al., 2009). 
Aripiprazole, which is often referred to as a “third-generation” antipsychotic, also 
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has a favorable side effect profile with few extrapyramidal effects (DeLeon et al., 
2003; Keck et al., 2004; Marder et al., 2003). The results of this thesis are 
consistent with the idea that the long-term effects of haloperidol on the cAMP and 
Akt pathways may underlie its adverse effects; whereas, the lack of persistent 
change in cAMP and Akt pathways after aripiprazole treatment may be 
responsible for its superior side effect profile. In regard to development, 
haloperidol and aripiprazole likely exert their unique long-term effects 
consistently across young and adult ages. With this in mind, these results reflect 
the minimal side effects reported after aripiprazole treatment in adults as well as 
children. With that being said, some studies have reported that aripiprazole 
causes increased extrapyramidal effects in younger ages when compared to 
second-generation antipsychotics (Amor, 2012; Doey, 2012; McKinney & Renk, 
2011). Perhaps children display elevated extrapyramidal effects after aripiprazole 
treatment because of increased D2 receptor upregulation that is independent of 
actions on the cAMP and Akt systems.  
 In terms of limitations, one concern regarding the translational relevance 
of this work is the dosage of aripiprazole (10 mg/kg/day) administered to rats, 
which is much higher than typical human doses (10-30 mg/kg/day). However, the 
different dosages were actually used to control elimination rate, which is much 
faster in rats than humans (Greenaway & Elbe, 2009; Mallikaarjun, Salazar, & 
Bramer, 2004; Shimokawa, Akiyama, Kashiyama, Koga, & Miyamoto, 2005). 
Another concern is the length of the drug abstinence period used in rats when 
70 
 
compared to the much longer abstinence periods experienced by humans. 
Although these time factors are difficult to compare, the drug abstinence periods 
used in this study likely map to human brain development and aging over months 
or years (Varela et al., 2014).  
 
Conclusion 
 Overall, the results of this thesis indicate that aripiprazole has different 
long-term effects on D2 receptor signaling pathways than haloperidol. 
Aripiprazole has less extreme or prolonged effects on D2 receptor signaling 
pathways, as evidenced by the lack of post-treatment upregulation in cAMP and 
Akt pathways. These results are consistent with the idea that the superior side 
effect profile of aripiprazole may be due to reduced D2 receptor upregulation in 
the dorsal striatum (Inoue et al., 1997). This thesis expands on this hypothesis, 
suggesting that D2 receptor functioning is important for determining how 
aripiprazole reduces psychosis and has fewer extrapyramidal effects. 
Specifically, haloperidol and aripiprazole both act to alter the affinity of D2 
receptors, which may explain their therapeutic effects in reducing the positive 
symptoms of schizophrenia. Additionally, upregulation of D2 receptors and, in 
turn, upregulation of proteins in the cAMP and Akt pathways may be partially 
responsible for side effects. However, making comparisons between animal 
studies and humans with schizophrenia is complicated, because the cellular 
environment differs substantially between rats and clinical populations (Pan et 
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al., 2016a). The cellular environment is important because aripiprazole is thought 
to have either agonist or antagonist actions depending on the level of 
dopaminergic activity which, of course, differs according to disease state and the 
brain areas being assessed (Pan et al., 2016b). Despite this caution, the results 
of this thesis indicate that aripiprazole does not affect the cAMP and Akt systems 
as intensely as haloperidol.  
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